Thromboembolic risks in patients with COVID-19: major concern to consider in our management

COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many propose...

Descripción completa

Detalles Bibliográficos
Autores principales: Temgoua, Mazou Ngou, Kuaté, Liliane Mfeukeu, Ngatchou, William, Sibetcheu, Aurelie, Toupendi, Zouliatou Nzina, Belobo, Grace, Ossa, Alice, Kingue, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2020
Materias:
Letter to the Editors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266474/
https://www.ncbi.nlm.nih.gov/pubmed/32528621
http://dx.doi.org/10.11604/pamj.2020.35.2.22945
Descripción
Sumario:COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many proposed drugs are under clinical trials. Considering the high incidence of thromboembolic events in critically ill patients with COVID-19, prevention of this disorder should be essential in order to reduce mortality in these patients.

Ejemplares similares